An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model.
about
Rapid isolation of dengue-neutralizing antibodies from single cell-sorted human antigen-specific memory B-cell culturesDengue Fever: Causes, Complications, and Vaccine StrategiesCan non-human primates serve as models for investigating dengue disease pathogenesis?Transcriptional Activation of Interferon-Stimulated Genes but Not of Cytokine Genes after Primary Infection of Rhesus Macaques with Dengue Virus Type 1Humanized Monoclonal Antibodies Derived from Chimpanzee Fabs Protect against Japanese Encephalitis Virus In Vitro and In VivoA Tetravalent Dengue Vaccine Based on a Complex Adenovirus Vector Provides Significant Protection in Rhesus Monkeys against All Four Serotypes of Dengue VirusA recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cellsImmunogenicity and Protective Efficacy of a Recombinant Subunit West Nile Virus Vaccine in Rhesus MonkeysDengue-1 envelope protein domain III along with PELC and CpG oligodeoxynucleotides synergistically enhances immune responsesA novel single-dose dengue subunit vaccine induces memory immune responsesCurrent progress in dengue vaccinesInduction of neutralization antibodies in mice by Dengue-2 envelope DNA vaccines.Report of an NIAID workshop on dengue animal models.Utility, limitations, and future of non-human primates for dengue research and vaccine developmentDengue vaccines: recent developments, ongoing challenges and current candidates.Dengue vaccines: strongly sought but not a reality just yetThe protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2.An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques.Next-generation dengue vaccines: novel strategies currently under development.Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunizationComplementary alternative medicine use among patients with dengue fever in the hospital setting: a cross-sectional study in Malaysia.Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial.Testing of novel dengue virus 2 vaccines in African green monkeys: safety, immunogenicity, and efficacyAn alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection.Potential of ancestral sylvatic dengue-2 viruses to re-emerge.A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits.TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis.Tick-borne Encephalitis Vaccines.A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates.Domain III of the envelope protein as a dengue vaccine target.DENV-2 subunit proteins fused to CR2 receptor-binding domain (P28)-induces specific and neutralizing antibodies to the Dengue virus in mice.Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4'-aminomethyl-trioxsalen) is highly immunogenic in mice.Strategies for the plant-based expression of dengue subunit vaccines.Challenges in reducing dengue burden; diagnostics, control measures and vaccines.Developing a dengue vaccine: progress and future challenges.Recent progress in dengue vaccine development.Production and testing of dengue virus strains suitable for human infection studies.Could an experimental dengue virus infection fail to induce solid immunity against homologous viral challenge in non-human primates?Development of a capillary zone electrophoresis method for dose determination in a tetravalent dengue vaccine candidate.
P2860
Q26700070-A9D303D6-7CB2-4C77-B3E6-C6A9B3BEA5EDQ26700082-DA5385C6-694C-4DEE-98E5-2203C8EDCD7CQ26825708-CE35A5B9-C881-425C-8365-46E2701659AAQ27480996-6D173C87-B065-4E83-B4D0-E12B0E8F822FQ27486404-DF70515F-0B80-4895-9DD1-E2C4ACFE1D96Q27486406-583EFC82-9E4C-4DF2-836F-0D2726251DE4Q27487992-D8282B86-CD93-48AB-BB57-3C7174C50559Q27489620-E8C32A07-1D22-4027-913C-6D5A2AA8F9DEQ28729951-B78426E9-A1F3-462F-B1F9-A7DEDDAFEDC4Q28741828-99755C51-3841-4689-9F7F-67A0D064E151Q33408300-46580590-6FA5-4CB0-8139-DD5016615824Q33961878-F998F099-2778-4629-9BD8-74618200FFD6Q34058747-BFCC5773-3DFC-4A16-AD64-B302B16C9485Q34238916-B057B5C0-5257-4C3B-95FA-D279A2748EAEQ34367194-B7302E7A-9DE2-4815-B2A2-35B86A1414DBQ35008771-7778FF30-9E35-4997-8EB6-2B9C9E10044EQ35236379-D56527B7-0EF3-4022-BE1A-8CC8BD6D05E4Q35272502-A4418D34-B3A5-44A0-95D0-765898A07D13Q35491639-4BBCEE33-D289-47C5-9900-58F673CBD380Q35548048-D130F9D8-E0FD-4556-8ECF-BA196B6884F7Q35828002-33B6A0CB-A7F6-4694-BCA9-C01288FDA071Q35908624-F0FCF247-8C21-409F-B926-6FD4FB74A375Q36026210-376BA63D-5F79-4AD1-A3AF-1ADFE0772534Q36450864-93F1073E-B23D-40E4-9C38-D9582593362AQ36667964-45A767EE-DB5A-4107-85C5-6251D80B9E78Q36718596-2E130623-CA54-4E96-B23C-51266217A7BEQ36849774-62E699E3-6411-40CB-A014-B529E5CF1260Q37120117-C1A7BB1D-77FB-442A-9349-37DA773925E0Q37127083-3A5750DE-AAE8-48EE-8DBB-E45DCD75C8B2Q37336762-15E0D3B5-03B6-4155-B5A6-130CB22BAC75Q37682895-0874E2D0-FDF3-4826-8484-E555B5C83241Q37694852-6200A23E-5DC8-47E7-848C-10D82B7B9287Q37694855-5101556C-DFFF-498E-9451-4646538B4252Q37812659-E0F58780-82E7-48B3-BA89-214DD61D06D9Q38140035-1D0F1042-152A-4B3B-8242-FE3C09D63291Q38201151-FA54924A-475D-427C-AEEA-ECECC3943DCEQ38303232-D477CD38-974D-4489-9B9A-2EDCDC8689C0Q38990645-A48BFF4F-0D56-4B1D-922D-8E72F6803EC4Q40130106-84A6D444-7FE9-475D-AC51-B2269180A567Q40140795-6CA81477-BA1E-4F4F-8DCA-E4812D800E49
P2860
An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
An evaluation of dengue type-2 ...... s in the rhesus macaque model.
@en
type
label
An evaluation of dengue type-2 ...... s in the rhesus macaque model.
@en
prefLabel
An evaluation of dengue type-2 ...... s in the rhesus macaque model.
@en
P2093
P1433
P1476
An evaluation of dengue type-2 ...... s in the rhesus macaque model.
@en
P2093
Beth-Ann Coller
David A Barvir
David Clements
David W Vaughn
Dirk Gheysen
Gary Bignami
Gerald Voss
Hou-Shu Houng
Iain Peters
J Robert Putnak
P304
P356
10.1016/J.VACCINE.2005.03.042
P407
P577
2005-08-01T00:00:00Z